Cingulate (CING) Accounts Payables (2021 - 2026)
Cingulate's (CING) quarterly Accounts Payables came in at $2.0 million in Q4 2025, up 60.25% YoY from $1.3 million in Q4 2024, and up 135.0% on a QoQ basis from $866245.0 in Q3 2025.
Cingulate (CING) Accounts Payables (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Accounts Payables data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Accounts Payables rose 60.25% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (up 60.25% YoY) and the FY2025 annual result came in at $2.0 million, up 60.25% from the prior year.
- Accounts Payables grew to $2.0 million in Q4 2025, from $866245.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $5.2 million in Q4 2023 to a low of $264687.0 in Q4 2021.
- A 5-year average of $1.2 million and a median of $860697.5 in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables surged 581.98% — and 2024, when it slumped 75.57%.
- Tracing CING's Accounts Payables over 5 years: stood at $264687.0 in 2021, then soared by 188.02% to $762357.0 in 2022, then surged by 581.98% to $5.2 million in 2023, then tumbled by 75.57% to $1.3 million in 2024, then surged by 60.25% to $2.0 million in 2025.
- The last three Accounts Payables figures came in at $2.0 million (Q4 2025), $866245.0 (Q3 2025), and $855150.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 866,245.00 |
| Mar 31, 2025 | 855,150.00 |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 906,215.00 |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 737,949.00 |
| Dec 31, 2023 | 5.20 Mn |
| Sep 30, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.61 Mn |
| Mar 31, 2023 | 599,033.00 |
| Dec 31, 2022 | 762,357.00 |
| Sep 30, 2022 | 392,798.00 |
| Jun 30, 2022 | 282,265.00 |
| Mar 31, 2022 | 556,326.00 |
| Dec 31, 2021 | 264,687.00 |